Skip to main content

Table 2 Healthcare and medication utilisation in the baseline year

From: Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study

  Total
No. 5230
Control
No. 4184
ICS cessation
No. 1046
p-value
Respiratory consultations in primary care 3.8 (± 3.6) 3.7 (± 3.4) 4.1 (± 4.0) 0.001
Exacerbations managed in primary care 1.0 (± 1.4) 1.0 (± 1.4) 1.0 (± 1.3) 0.41
Exacerbations requiring A&E attendance or hospitalisation 0.08 (± 0.32) 0.08 (± 0.31) 0.09 (± 0.35) 0.21
Total exacerbations 1.1 (± 1.4) 1.1 (± 1.4) 1.1 (± 1.4) 0.68
Pneumonia-coded consultation, n (%) 153 (2.9%) 101 (2.4%) 52 (5.0%) < 0.001
ICS prescriptions 11.1 (± 3.7) 10.9 (± 3.5) 12.3 (± 4.3) < 0.001
ICS adherence (medication possession ratio) 98.4 (± 37.9) 96.1 (± 37.5) 107.8 (± 38.2) < 0.001
LABA prescriptions 11.2 (± 4.2) 10.8 (± 3.8) 12.6 (± 5.1) < 0.001
LAMA prescriptions 9.6 (± 4.7) 9.3 (± 4.6) 11.1 (± 4.8) < 0.001
SABA prescriptions 11.4 (± 9.9) 11.4 (± 9.7) 11.6 (± 10.5) 0.66
Theophylline prescriptions, n (%) 440 (8.4%) 384 (9.2%) 56 (5.4%) < 0.001
Carbocysteine prescriptions, n (%) 1142 (21.8%) 920 (22.0%) 222 (21.2%) 0.62
Antibiotic prescriptions, n (%) 2571 (49.2%) 2078 (49.7%) 493 (47.1%) 0.15
Oral corticosteroid prescriptions, n (%) 3122 (59.7%) 2552 (61.0%) 570 (54.4%) < 0.001
  1. Data are means (± standard deviation), unless otherwise specified